Xeris Biopharma Holdings (XERS) EBT Growth (1y) (2021 - 2026)
Xeris Biopharma Holdings (XERS) EBT Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 48.64% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -1.94% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -393.93% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -24.84% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 92.01% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1,578.91% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 45.00% |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 124.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 124.23% |
| Dec 31, 2025 | 316.72% |
| Sep 30, 2025 | 103.26% |
| Jun 30, 2025 | 86.48% |
| Mar 31, 2025 | 50.62% |
| Dec 31, 2024 | 62.48% |
| Sep 30, 2024 | -52.17% |
| Jun 30, 2024 | 30.52% |
| Mar 31, 2024 | -10.92% |
| Dec 31, 2023 | -2.70% |
| Sep 30, 2023 | 43.50% |
| Jun 30, 2023 | 22.65% |
| Mar 31, 2023 | 50.67% |
| Dec 31, 2022 | 73.88% |
| Sep 30, 2022 | 14.76% |
| Jun 30, 2022 | 3.60% |
| Mar 31, 2022 | -85.33% |
| Dec 31, 2021 | -132.37% |
| Sep 30, 2021 | -62.56% |